Hims Falls on Fears Over Copycat Drugs Mired in Legal Risk (3)

Hims & Hers Health Inc. shares fell on continued uncertainty about whether the telehealth company can keep selling copycat weight-loss drugs that are mired in legal and regulatory risks.

The stock slid as much as 11% when the markets opened in New York on Tuesday, following a weaker outlook for the first quarter and the company’s refusal to answer questions about its ongoing ability to sell compounded versions of Novo Nordisk A/S’s Ozempic and Wegovy, a class of drugs known as GLP-1s.

Sales for the year will be between $2.7 billion and $2.9 billion, the telehealth company saidMonday, ...